Johnson & Johnson’s Stelara psoriasis drug has shown effectiveness against Crohn’s disease in a second late-stage trial, the company said on Friday, bolstering prospects of its approval for the additional use. The Phase 3 study showed Stelara induced remissions in moderate to severe Crohn’s disease patients who had previously failed to benefit from TNF inhibitors, a leading class of medicines for the inflammatory bowel disease. J&J presented the favorable data on Friday at the 11th Congress of the European Crohn’s and Colitis Organization in Amsterdam.
Continued here:
J&J psoriasis drug Stelara eases Crohn’s disease in second trial
